Rational Design of an Epidermal Growth Factor Receptor Vaccine: Immunogenicity and Antitumor Research
Biomolecules · 2024
DOI: 10.3390/biom14121620 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biomolecules, 2024. Verfasst von Yifei Liu und 2 weiteren Autor:innen. Beteiligte Einrichtung: College of Life Sciences, Wuhan University, Wuhan 430072, China. Hauptthemen laut MEDLINE: ErbB Receptors, Cancer Vaccines. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 75 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
The epidermal growth factor receptor (EGFR) is frequently overexpressed in a variety of human epithelial tumors, and its aberrant activation plays a pivotal role in promoting tumor growth, invasion, and metastasis. The clinically approved passive EGFR-related therapies have numerous limitations. Seven EGFR-ECD epitope peptides (EG1-7) were selected through bioinformatics epitope prediction tools including NetMHCpan-4.1, NetMHCIIpan-3.2, and IEDB Consensus (v2.18 and v2.22) and fused to the translocation domain of diphtheria toxin (DTT). The A549 tumor model was successfully established in a murine mouse model. The vaccine was formulated by combining the adjuvants Alum and CpG and subsequently assessed for its immunogenicity and anti-tumor efficacy. DTT-EG (3;5;6;7) vaccines elicited specific humoral and cellular immune responses and effectively suppressed tumor growth in both prophylactic and therapeutic mouse tumor models. The selected epitopes EG3 (HGAVRFSNNPALCNV145-159), EG5 (KDSLSINATNIKHFK346-360), EG6 (VKEITGFLLIQAWPE398-412), and EG7 (LCYANTINWKKLFGT469-483) were incorporated into vaccines for active immunization, representing a promising strategy for the treatment of tumors with overexpressed epidermal growth factor receptor (EGFR). The vaccine design and fusion method employed in this study demonstrate a viable approach toward the development of cancer vaccines.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- College of Life Sciences, Wuhan University, Wuhan 430072, China.
ORCID-Profile: Zhongliang Zheng
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Liu, Y., Liu, Z., & Zheng, Z. (2024). Rational Design of an Epidermal Growth Factor Receptor Vaccine: Immunogenicity and Antitumor Research. Biomolecules. https://doi.org/10.3390/biom14121620
Vancouver
Liu Y, Liu Z, Zheng Z. Rational Design of an Epidermal Growth Factor Receptor Vaccine: Immunogenicity and Antitumor Research. Biomolecules. 2024. doi:10.3390/biom14121620
BibTeX
@article{Liu2024,
author = {Liu, Yifei and Liu, Zehui and Zheng, Zhongliang},
title = {Rational Design of an Epidermal Growth Factor Receptor Vaccine: Immunogenicity and Antitumor Research},
journal = {Biomolecules},
year = {2024},
doi = {10.3390/biom14121620}
}
EUVIMED